anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Background and Objectives: Repetitive ankle sprains lead to mechanical instability of the ankle. Patients with chronic ankle instability may experience decreased muscle strength and limited postural control. This study investigated the effects of a hip-strengthening exercise program on muscle strength, balance, and function in patients with chronic ankle instability. Materials and Methods: A total of 30 patients participated in the study and were randomly assigned to the two groups. Among the 30 participants, 14 were assigned to the hip joint-strengthening exercise group and 16 to the control group. The experimental group underwent a hip-strengthening exercise program and received training for 40 min per session twice a week for four weeks. The control group received the same frequency, duration, and number of sessions. Measurements were performed before and after the training period to assess changes in hip strength, balance, and function. Results: In the within-group and between-group comparisons, both groups showed significant differences in hip joint strength, static balance, dynamic balance, and function (FAAM; foot and ankle ability measures) (p < 0.05). Statistically significant differences were observed in the time × group interaction effects among the hip abductors and external rotation in hip joint strength, path length in static balance, posterolateral and posteromedial in dynamic balance, and FAAM-ADL and FAAM-SPORT functions (p < 0.05). Conclusions: Accordingly, this study confirmed that hip joint-strengthening exercises have a positive effect on the strength, balance, and function of patients with chronic ankle instability, and we believe that hip joint-strengthening exercises will be recommended as an effective intervention method for patients suffering from chronic ankle instability.
Intravenous (IV) daptomycin was dosed as follows: age 12 years to \<18 years (7 mg/kg); age 7 years to \< 12 years (9 mg/kg); age 24 months to \<7 years (12 mg/kg); age 12 months to \<24 months (12 mg/kg). Drug was infused over 60 minutes ± 10 minutes once daily followed by up to 3 dummy infusions every 6 hours (q6h) infused over 60 (± 10) min to maintain the blind.
BACKGROUND: Despite trimodality treatment, 10% to 20% of patients with esophageal cancer experience interval metastases after surgery. Restaging may identify patients who should not proceed to surgery, as well as a subgroup with limited metastases for whom long-term disease-control can be obtained. This study aimed to determine the proportion of patients with interval metastases after neoadjuvant chemoradiotherapy (nCRT) and to evaluate treatment and survival.
METHODS: Patients who had cT2-4aN0-3M0 esophageal cancer treated with nCRT were identified from a trial database. Metastases detected up to 14 weeks after nCRT on 18F-FDG-PET/CT or during surgery were categorized as oligometastases (≤3 lesions located in one single organ or one extra-regional lymph node station) or as non-oligometastases. The primary outcome was the proportion of patients with metastases after nCRT. The secondary outcomes were overall survival (OS) and the site and treatment of metastases.
RESULTS: Between 2013 and 2021, 973 patients received nCRT, and 10.3% had interval metastases. Of 100 patients, 30 (30%) had oligometastases, located mostly in non-regional lymph nodes (33.3%) or bones (26.7%). The median OS of this group was 13.8 months (95% confidence interval [CI] 9.2-27.1 months). Of 30 patients, 12 (40%) with oligometastases underwent potentially curative treatment, with a median OS of 22.8 months (95% CI 10.4-NA). The patients with non-oligometastases underwent mostly systemic therapy or BSC and had a median OS of 9 months (95% CI 7.4-10.9 months).
CONCLUSIONS: Interval metastases were detected in about 10% of patients after nCRT, underscoring the importance of re-staging with 18F-FDG-PET/CT for those who proceed to surgery. A favorable survival might be accomplished for a subgroup of patients with oligometastases.
PROBLEM TO BE SOLVED: To provide a method of linking a symptom-relaxing agent, which treats an affected area, to the affected site through cloth and the like by utilizing the delivery by means of vaporization-transpiration of alcohol. SOLUTION: The solution, which is obtained by dissolving a plant extract or a medicine into an alcohol and stored in a small spray vessel, is foggily jet out on cloths or papers 6 and previously permeated into the cloths or papers 6. Then, the solution is breathed in the inside of the nasal cavity 8 or the throat 9. By this process, the nasal turbinates 10, particularly the area deep in the lower part of the nasal turbinates 10 difficult to apply medicines, can be treated. In addition, the plant extract or the solution of medicine can be applied to the throat 9 to treat the affected area. Further, by carrying out the above- described application, the plant extract or the solution of medicine along with an alcohol can be applied to the affected part in eyes 13 to treat the affected part. Furthermore, the symptom is decreased by smelling the odor and the mental peace is also obtained.
FIELD: medicine, surgery. SUBSTANCE: methotrexate is administrated into mass of keloid scar in the dose 10 mg per 10 cm 2  but not above 20 mg per all scar. In 7- 10 days surgery keloplasty is carried out with preliminary ischemia of tissue. After keloplasty intracutaneous seams are applied. Beginning from the first after operation methotrexate is taken orally in the dose 2.5 mg per a day up to the total dose 12.5 mg. Method ensures to prevent the repeated scars formation. Invention can be used for treatment of keloid scar. EFFECT: improved method of treatment. 1 ex
The present invention discloses a pure Chinese patent medicine substance for treating chloasma, pigment and facial speckle diseases, which is prepared from the raw material of peach seed, apricot kernel, Chinese date, licorice root, fennel, table salt, dried orange peel and mulberry fruit. The medicine of the present invention has the functions of promoting blood circulation for removing blood stasis, loosening bowels, relieving constipation, dredging the liver, promoting qi circulation, expanding the blood vessel, promoting blood circulation for removing meridian obstruction, beautifying the face, nourishing blood, invigorating the lung and the kidney, strengthening the spleen, nourishing the face and strengthening the body. The medicine treats both the manifestations and the root causes of diseases, and has rapid medicine potency. The medicine can eliminate risk factors which cause the occurrence and the development of chloasma, pigment and facial speckle diseases as soon as possible, and alleviate pain for patients of middle ages, who suffer from chloasma, pigment and facial speckle diseases for a long time. The present invention is a novel discovery and a novel development of the methods and the medicines of beautification and senescence resistance theories. The medicine is a regulating agent for the health of people of middle and old ages, and is an optimal medicine for removing speckles, regulating fat, dredging pulses and resisting senescence for people of middle and old ages, who suffer from viscera asthenia. The formula can moisten facial color, strengthen the body and resist facial senescence by invigorating the functions of the spleen and the stomach, transporting and infusing nutrients for the whole body and nourishing the skin.
PCT No. PCT/SE79/00132 Sec. 371 Date Feb. 11, 1981 Sec. 102(e) Date Jan. 9, 1981 PCT Filed Jun. 11, 1979 PCT Pub. No. WO80/02805 PCT Pub. Date Dec. 24, 1980.A process for the treating of and/or removal of substances from a liquid, especially whole blood, via a semipermeable microporous membrane (13, 14, 15) through adsorption and/or biological reaction by means of a biologically active material. Said whole blood is exposed to pressure variations at the membrane surface in a way such that a penetrating fraction of said whole blood is flowing in an alternating flow path through the membrane walls for contacting said biologically active material. Said biologically active material is asymmetrically immobilized in and on the surface of the side of said membrane that faces away from said whole blood. Alternatively, said biologically active material may be bound to an unsoluble matrix behind said membrane. Said membrane is for example provided within a casing (7, 8, 9) comprising inlet (10) and outlet (11) for said whole blood. The space between said casing and said membrane is via a connecting nipple (12) in communication with for example an expansion chamber for the provision of pressure variations. By means of the device (3) it is possible to perform said process in one and the same step and by means of one and the same pumping system.
The organic starting material is extracted in a liquefied gas, and the active substance complex obtained in this way is immediately dissolved/dispersed with addition of a solubilizer. Thereafter, the liquefied gas is evaporated, resulting in the active substance complex in solubilized form. Suitable solubilizers are poloxamers, for example Lutrol F68, but also Tween polysorbate or E445 (glycerol esters of wood rosins). The organic swelling material may consist of natural or genetically modified, vegetable, animal or human material. One or more additives can be added if necessary, for example to alter the consistency or the surface tension of the solubilizate. The products manufactured in this way exhibit a high bioavailability, but can also be employed for commercial industrial purposes.
Pentoxifylline (PTX) is a phosphodiesterase inhibitor that is used clinically to treat patients with peripheral vascular disorders. In addition to its hemorheologic activity, PTX possesses potent anti-inflammatory and immunomodulatory properties. In vivo, PTX has shown its ability to attenuate nephrotic syndrome secondary to membranous glomerulonephritis and lupus nephritis, and to reduce subnephrotic proteinuria of early and advanced diabetic nephropathy. However, the anti-proteinuric effect of PTX has been traditionally attributed to down-regulation of tumor necrosis factor (TNF)-alpha. Whether or not other inflammatory mediators are also affected by PTX has never been studied. Our previous works have shown that PTX can inhibit cytokine or albumin-induced monocyte chemoattractant protein (MCP)-1 production in vitro, and attenuate proteinuria in association with suppression of renal MCP-1 messenger ribonucleic acid expression in experimental glomerulonephritis. More recently, we have found that PTX lowers proteinuria by modulating renal MCP-1 production in a subgroup of human glomerular diseases. In this study, we aim to investigate whether combination of PTX and corticosteroids results in additive reduction in proteinuria, and higher remission rates in patients with primary nephrotic syndrome. The secondary objective is to study whether PTX monotherapy can be effective in patients with primary nephrotic syndrome not suitable for or intolerant of corticosteroid therapy.

This study is a prospective, open-labeled, comparative study including primary nephrotic patients randomized into 2 groups. Group A receives oral PTX plus oral prednisolone, whereas group B receives oral prednisolone alone. The active treatment duration is 1 year for both subgroups. The dose for PTX will be 1,200 mg/day (for estimated glomerular filtration rate (GFR) ≧60 ml/min) or 800 mg/day (estimated GFR 59-30 ml/min) x 6 months, followed by stepwise reduction (800 mg/day x 6 M, 400 mg/day x 6 M and discontinued at 18 M). The dose for prednisolone will be 1 mg/kg/day for the initial 3 months, then the dose will be gradually tapered, thus by 6 months the dose will be 0.5 mg/kg/day, and at 12 months the dose will be reduced to around 5-10 mg/day, and discontinued at 18 M. For patients not considered suitable for (eg., active chronic hepatitis B virus or hepatitis C virus infection), or intolerance of (eg., concomitant diabetes mellitus, active peptic ulcer disease) standard corticosteroid therapy, PTX 1,200 mg/day will be administered to them for a total of 1 year. Serum and urine specimens will be collected before initiation of therapy (day 0), and at month 1, 3, 6, and 12 after the commencement of therapy. GFR will be calculated by Cockcroft-Gault and simplified Modification of Diet in Renal Disease (MDRD) formula. Urinary protein excretion will be quantitated by spot urine protein/creatinine ratio. All biochemical and immunological analyses will be performed by the Department of Laboratory Medicine, National Taiwan University Hospital. Serum and urine samples will be measured for inflammatory mediators and podocyte markers by using commercial ELISA kits.
Eugenia flavescens is a species cultivated in Brazil for food purposes. Given the potential application of essential oils from plants of the genus Eugenia, this study was carried out to investigate the chemical composition, acute toxicity, antioxidant, antinociceptive, gastroprotective activities, and possible mechanisms of action of the essential oil from the leaves of E. flavescens (EOEf). The EOEf was extracted by hydrodistillation, and the chemical composition was obtained using gas chromatography-mass spectrometry. The antioxidant activity was evaluated, as well as the acute toxicity and the antinociceptive and anti-inflammatory effects in mice. In addition, the gastroprotective effect was investigated using an acute gastric lesion model, considering possible mechanisms of action. The major components found in the EOEf were guaiol (19.97%), germacrene B (12.53%), bicyclogermacrene (11.11%), and E-caryophyllene (7.53%). The EOEf did not cause signs of toxicity in the acute oral toxicity test and showed in vitro antioxidant activity with IC50 ranging from 247.29 to 472.39 µg/mL in the tests ABTS and DPPH. In the nociceptive test, EOEf showed a 72.05% reduction in nociception at a dose of 100 mg/kg. In evaluating the anti-inflammatory effect, the essential oil inhibited paw edema by 95.50% and 97.69% at doses of 50 and 100 mg/kg. The results showed that EOEf has a gastroprotective effect, acting through the sulfhydryl compounds (-SH), nitric oxide (NO), and synthesis PGE2 pathways. The results suggested that EOEf is a promising source of constituents with antioxidant, antinociceptive, anti-inflammatory, and gastroprotective properties with application in the food and pharmaceutical industries.
The invention discloses recombinant collagen and an expression method and application thereof, and belongs to the technical field of biochemical engineering. The invention provides recombinant collagen, which is prepared by splicing type III human collagen and type I human collagen alpha 2 amino acid sequences. The recombinant collagen is expressed by adopting the human embryo kidney cells Expi293F, the protein expression quantity is high, and the expression of the recombinant collagen with large molecular weight is realized. The activity research also shows that the expressed recombinant collagen has good activity of promoting cell migration, and the recombinant collagen III+I with the fusion tag has good stability at 4 ℃. In addition, cell activity studies indicate that recombinant type III collagen expressed by human cells has better activity of promoting cell migration than commercially available type III collagen. These results demonstrate that the human cell expression system facilitates the expression of highly active, large molecular weight recombinant collagen.
OBJECTIVES: The aim of this study was to characterise the presentation, treatment, and management of adolescent athlete low back pain (LBP) as diagnosed in a clinical setting. The objectives were to 1) identify diagnoses associated with LBP in adolescent athletes; 2) categorise the differences in LBP diagnosis and presentation by sport, sex, BMI, and age; and 3) examine treatment and management methods of LBP in adolescent athletes.
DESIGN: Retrospective chart review.
METHODS: This retrospective medical chart review was conducted in the Sports Medicine Division of Boston Children's Hospital (BCH), a tertiary paediatric academic hospital. Data were collected and analysed from 363 adolescent athletes who had experienced LBP between 2015 and 2020. Chi-squared tests for association were used to assess for associations between LBP diagnoses and age, sex, BMI, and sport. Statistical analysis was conducted using SAS software version 9.4 (SAS Institute, Cary NC).
RESULTS: Non-specific LBP was the most common LBP diagnosis amongst 363 adolescent athletes with LBP (34 %). This was closely followed by spondylolysis (28 %). There was a higher proportion of female athletes amongst participants diagnosed with facet-joint related pain (90 %) and SI-joint related pain (89 %) compared to the proportion of female athletes amongst participants diagnosed with spondylolysis (50 %). There was a high rate of diagnostic MRI usage in this cohort. Commonly used management techniques in this cohort were diagnostic MRI, physical therapy, relative rest, and bracing.
CONCLUSIONS: An awareness of the sex-based differences in adolescent athlete LBP diagnoses may be useful for clinicians. It may be important to refine methods of diagnosis of LBP in this group, as there was a high rate of diagnostic MRI use. Future research should be directed towards the development of management guidelines specific to LBP in adolescent athletes to assist in the optimal management of this diagnosis.
The use of Oxycodone Hydrochloride and Acetaminophen Tablets in patients with acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment is contraindicated.

Patients with Chronic Pulmonary Disease: Oxycodone Hydrochloride and Acetaminophen Tablets-treated patients with significant chronic obstructive pulmonary disease or cor pulmonale, and those with a substantially decreased respiratory reserve, hypoxia, hypercapnia, or pre-existing respiratory depression are at increased risk of decreased respiratory drive including apnea, even at recommended dosages of Oxycodone Hydrochloride and Acetaminophen Tablets [see WARNINGS: Life-Threatening Respiratory Depression].

Elderly, Cachetic, or Debilitated Patients: Life-threatening respiratory depression is more likely to occur in elderly, cachectic, or debilitated patients because they may have altered pharmacokinetics or altered clearance compared to younger, healthier patients [see WARNINGS: Life-Threatening Respiratory Depression].

Monitor such patients closely, particularly when initiating and titrating Oxycodone Hydrochloride and Acetaminophen Tablets and when Oxycodone Hydrochloride and Acetaminophen Tablets are given concomitantly with other drugs that depress respiration [see WARNINGS: Life-Threatening Respiratory Depression]. Alternatively, consider the use of non-opioid analgesics in these patients.

###  Adrenal Insufficiency 

Cases of adrenal insufficiency have been reported with opioid use, more often following greater than one month of use. Presentation of adrenal insufficiency may include non-specific symptoms and signs including nausea, vomiting, anorexia, fatigue, weakness, dizziness, and low blood pressure. If adrenal insufficiency is suspected, confirm the diagnosis with diagnostic testing as soon as possible. If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. Wean the patient off of the opioid to allow adrenal function to recover and continue corticosteroid treatment until adrenal function recovers. Other opioids may be tried as some cases reported use of a different opioid without recurrence of adrenal insufficiency. The information available does not identify any particular opioids as being more likely to be associated with adrenal insufficiency.
BACKGROUND: In the pediatric population, Staphylococcus aureus infections are responsible for increased morbidity and mortality, length of hospitalization and the cost of inpatient treatment. The aim of this study is to describe the antimicrobial resistance profile of S. aureus isolated in clinical specimens from pediatric patients admitted to a tertiary hospital in Rio de Janeiro, Brazil.
METHODS: Culture reports and medical records of hospitalized patients under 18 years of age with S. aureus infections between January 2015 and December 2022 were retrospectively analyzed. Information was collected on recent antibiotic use, previous hospital admission, inpatient unit, clinical specimen, time of infection (community or nosocomial), classification according to susceptibility to methicillin (methicillin sensitive - MSSA or methicillin resistant - MRSA) and sensitivity to other antimicrobials. We analyzed the distribution of the sensitivity profile of S. aureus infections over the 7 years evaluated in the study.
RESULTS: Were included 255 unique clinical episodes, among which the frequencies of MSSA and MRSA were 164 (64%) and 91 (36%), respectively. Over the 7 years evaluated, there was stability in the prevalence percentage, with a predominance of MSSA in the range of 60 to 73.3%, except in 2020, when there was a drop in the prevalence of MSSA (from 73.3% in 2019 to 52.5%) with an increase in MRSA (from 26.7% in 2019 to 47.5%). Ninety-seven (38%) infections were community-acquired and 158 (62%) were healthcare-associated. The main clinical specimens collected were blood cultures (35.2%) and wound secretions (17%). The MRSA isolates presented percentages of sensitivity to trimethoprim-sulfamethoxazole from 90.4 to 100%, and to clindamycin from 77 to 89.8% in MRSA healthcare associated and MRSA community respectively.
CONCLUSION: There was a constant predominance in the prevalence of MSSA with percentage values ​​maintained from 2015 to 2022, except in 2020, in which there was a specific drop in the prevalence of MSSA with an increase in MRSA. MSSA infections are still predominant in the pediatric population, but MRSA rates also present significant values, including in community infections, and should be considered in initial empiric therapy.
The invention discloses a traditional Chinese medicine preparation for treating tuberculosis of spine. The preparation is prepared from the following raw medicines in parts by weight: angelica, the rhizome of chuanxiong, radix rehmanniae preparata, peach kernels, safflower, centipede, eupolyphaga, earthworm, buttercup root, whole worm, rhizoma cibotii, eucommia bark, south dodder seed, rhizoma drynariae, fructus psoraleae and liquorice. The preparation can be prepared into is pills, tablets, oral liquid preparations or capsule preparations by the traditional or modern preparation processes. The medicines jointly have the functions of enriching the blood and activating blood circulation, eliminating stasis and activating meridians, tonifying livers and stomachs and strengthening waists and knees. The preparation improves the human body immune function through oral administration and has confirmed curative effect on tuberculosis of spine caused by various reasons. The preparation has the advantages of quick effect, obvious treatment effect, good tolerance, low cost and no any toxic or side effect.
PURPOSE: A composition containing Nardostachyos Rhizoma extract is provided to suppress lung cancer cell growth and to induce lung cancer cell apoptosis. CONSTITUTION: A composition for preventing and treating lung cancer contains Nardostachyos Rhizoma ethanol extract as an active ingredient. The ethanol extract is prepared by extracting at 50 Deg. C. for 24 hours and drying and concentrating the extract at 45 Deg. C. The ethanol is 95% ethanol. The composition also contains pharmaceutically acceptable carrier or diluent. A cosmetic composition for preventing lung cancer contains the ethanol extract containing cosmetically acceptable additive. [Reference numerals] (AA) Nardostachys jatamansi